By Cristina Gallardo
The U.S. drug regulator declared that the shortage of weight-loss medications Wegovy and Ozempic has been resolved, Danish pharma giant Novo Nordisk said.
The Food and Drug Administration's announcement confirms that the U.S. supply of these prescription-only drugs now meets or exceeds the current and projected demand in the country, the pharmaceutical company said Friday.
Novo Nordisk added that it continues to produce Wegovy and Ozempic around the clock, seven days a week, in order to meet the sky-rocketing demand.
"No one should have to compromise their health due to misinformation and reach for fake or illegitimate knock-off drugs that pose significant safety risks to patients," said Dave Moore, executive vice president for U.S. Operations at Novo Nordisk.
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
February 21, 2025 10:30 ET (15:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.